Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LX7101 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Low dose LX7101 | EXPERIMENTAL | Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye) |
| High dose LX7101 | EXPERIMENTAL | Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye) |
| LX7101 Vehicle | PLACEBO_COMPARATOR | Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye) |
| Name | Type | Description |
|---|---|---|
| LX7101 (0.125%) | DRUG | Subjects will receive 0.125% LX7101 |
| LX7101 (0.25%) | DRUG | Subjects will receive 0.25% LX7101 |
| LX7101 Vehicle | DRUG | Subjects will receive vehicle |
Inclusion Criteria: * Adults ≥18 years of age * Documented diagnosis of POAG or OHT, in both eyes * Willing and able to provide written informed consent Exclusion Criteria: * History of any form of glaucoma in either eye, other than POAG * Subjects who are unwilling or unable to discontinue conta...
LX7101 is an investigational small molecule being developed for primary open-angle glaucoma, a condition that damages the optic nerve. It was studied in patients with primary open-angle glaucoma or ocular hypertension. The drug is in Phase 1 clinical development and is not yet approved by the FDA.
LX7101 is a small molecule, but its specific molecular target has not been disclosed. It is being investigated for its safety, tolerability, and efficacy in lowering eye pressure in patients with primary open-angle glaucoma or ocular hypertension. The mechanism of action is not publicly detailed.
LX7101 is being developed by Lexicon Pharmaceuticals, Inc., a biopharmaceutical company. The company's stock trades under the ticker symbol LXRX. The drug is in Phase 1 clinical development for primary open-angle glaucoma.
LX7101 is in Phase 1 clinical development. It has completed one Phase 1 trial, and the drug remains investigational, meaning it has not been approved by the FDA. The completed trial evaluated the drug's safety, tolerability, and efficacy in patients with primary open-angle glaucoma or ocular hypertension.
LX7101 has one completed Phase 1 clinical trial, identified as NCT01528111. This study evaluated the safety, tolerability, and efficacy of LX7101 in subjects with primary open-angle glaucoma or ocular hypertension. The trial was randomized, double-blind, and placebo-controlled, enrolling 63 participants in the United States.